Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportHematologic Malignancies

18F FDG PET Radiomics features result in more accurate prediction of outcome for DLBCL patients than currently used IPI score

Jakoba Eertink, Gerben Zwezerijnen, Simone Pieplenbosch, Sanne Wiegers, Pieternella Lugtenburg, Ulrich Dührsen, Andreas Hüttmann, Lars Kurch, Christine Hanoun, Sally Barrington, N George Mikhaeel, Luca Ceriani, Emanuele Zucca, Sandor Czibor, Tamás Györke, Martine Chamuleau, Otto Hoekstra, Henrica C.W. de Vet, Ronald Boellaard and Josée Zijlstra
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 2490;
Jakoba Eertink
1Amsterdam UMC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerben Zwezerijnen
1Amsterdam UMC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone Pieplenbosch
1Amsterdam UMC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanne Wiegers
1Amsterdam UMC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pieternella Lugtenburg
2Erasmus MC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Dührsen
3Universitätsklinikum Essen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Hüttmann
4University of Duisburg-Essen, University Hospital Essen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Kurch
5Universitätsklinikum Leipzig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Hanoun
6Uniklinikum Essen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Barrington
7Kings College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N George Mikhaeel
8Guy’s and St Thomas’
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Ceriani
9IIMSI -EOC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emanuele Zucca
10Ente Ospedaliero Cantonale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandor Czibor
11Semmelweis University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamás Györke
11Semmelweis University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine Chamuleau
1Amsterdam UMC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otto Hoekstra
1Amsterdam UMC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrica C.W. de Vet
12Amsterdam UMC, VU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Boellaard
13Vumc, Dept. Nuclear Medicine & PET Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josée Zijlstra
14Amsterdam UMC UMC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

2490

Introduction: Up to one-third of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients relapse or fail to achieve complete remission following first-line treatment. Adding PET radiomics features to currently used predictors may improve the identification of poor prognosis patients. The objective of this study was to externally validate the radiomics model developed in the HOVON-84 trial (Eertink et al, EJNMMI 2021) using datasets from other DLBCL studies within the PETRA database and to identify the optimal model to predict outcome in the PETRA database by combining radiomics features and clinical parameters.

Methods: 1092 newly diagnosed DLBCL patients with baseline 18F-FDG PET/CT scans with 2 year follow up in 7 studies in the PETRA database (https://petralymphoma.org) were included. Primary outcome was 2-year time to progression (TTP). 274 patients had progression within 2 years. Patients who died without progression within 2 years were not included in this analysis. Lesions were delineated using a fully automated preselection of 18F-FDG avid structures defined by a standardized Uptake Value (SUV) ≥ 4.0 and volume >3mL. Missed lesions were added and non-tumor regions were removed using the ACCURATE tool. 23 radiomics features were extracted: 5 conventional PET features (SUVmax, SUVmean, SUVpeak, total lesion glycolysis and metabolic tumor volume (MTV)) and 18 dissemination features (number of lesions, 4 features quantifying distance (Cottereau et al, JNM 2020), 10 features quantifying the differences in intensity and 3 features quantifying the differences in volume between lesions) using RaCat software (Pfaehler et al, Plos One 2019). We tested the predictive value of 1) the currently used international prognostic index (IPI) score, 2) the HOVON-84 model (MTV, SUVpeak, the maximum distance between the largest lesion and any other lesion (Dmaxbulk), performance status and age) and 3) a model that combined radiomics features and individual components of the IPI score (PETRA model). For the PETRA model we applied logistic regression with backward feature selection. Survival curves were compared using the log rank test. Model performance was assessed using repeated cross-validation (5 folds, 2000 repeats) yielding the mean receiver-operator-characteristics curve integral (AUC). High- and low-risk groups were defined based on prevalence of events. Diagnostic performance was assessed using the positive predictive value.

Results: The categorical IPI score (model 1) yielded a cross-validated AUC (CV-AUC) of 0.64 ± 0.04 (AUC of individual datasets: 0.59-0.69; Figure 1A). The HOVON-84 trial (model 2) yielded a CV-AUC of 0.72 ± 0.04, this model was predictive of outcome in all 7 individual datasets within PETRA (AUC: 0.65-0.83). After backward feature selection, a combination of MTV, the maximum difference in intensity between the largest lesion and any other lesion (DSUVpeakbulk), DmaxBulk, lactate dehydrogenase levels and performance status resulted in the highest model performance for model 3 with a CV-AUC of 0.73 ± 0.04. This model was also predictive of outcome for all individual studies (AUC: 0.70-0.83; Figure 1B). High-risk patients according to model 3, had a 2-year TTP of 58.8% (95% CI: 53.2-64.9) which was significantly lower (p < 0.001) than the survival of low-risk patients (85.9% (95% CI: 83.6-88.3)). The positive predictive value increased from 28.1% (95% CI: 24.0-32.7) for IPI based high-risk patients (210 patients) to 46.0% (95% CI: 41.2-50.8) for PETRA based high-risk patients (274 patients).

Conclusions: In concordance with the HOVON-84 data, combining quantitative radiomics features extracted from baseline 18F-FDG PET/CT scans with components of the IPI score significantly improved identification of patients at risk of relapse when treated with standard first-line treatment regimens. Moreover, comparable radiomics features were selected in the HOVON-84 and PETRA prediction models.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F FDG PET Radiomics features result in more accurate prediction of outcome for DLBCL patients than currently used IPI score
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
18F FDG PET Radiomics features result in more accurate prediction of outcome for DLBCL patients than currently used IPI score
Jakoba Eertink, Gerben Zwezerijnen, Simone Pieplenbosch, Sanne Wiegers, Pieternella Lugtenburg, Ulrich Dührsen, Andreas Hüttmann, Lars Kurch, Christine Hanoun, Sally Barrington, N George Mikhaeel, Luca Ceriani, Emanuele Zucca, Sandor Czibor, Tamás Györke, Martine Chamuleau, Otto Hoekstra, Henrica C.W. de Vet, Ronald Boellaard, Josée Zijlstra
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2490;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F FDG PET Radiomics features result in more accurate prediction of outcome for DLBCL patients than currently used IPI score
Jakoba Eertink, Gerben Zwezerijnen, Simone Pieplenbosch, Sanne Wiegers, Pieternella Lugtenburg, Ulrich Dührsen, Andreas Hüttmann, Lars Kurch, Christine Hanoun, Sally Barrington, N George Mikhaeel, Luca Ceriani, Emanuele Zucca, Sandor Czibor, Tamás Györke, Martine Chamuleau, Otto Hoekstra, Henrica C.W. de Vet, Ronald Boellaard, Josée Zijlstra
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2490;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A Deep Learning-Aided Automated Method for Calculating Metabolic Tumor Volume in Diffuse Large B-cell Lymphoma
  • Role of FDG PET-CT in the evaluation of extramedullary involvement in multiple myeloma
  • Role of 18F-FDG PET/CT in evaluating suspected hepatic involvement in staging Langerhans Cell Histiocytosis.
Show more Hematologic Malignancies

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire